Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs1

Journal of Immunology

Volumn 167, Issue 9, 2001, Pages 4878-4886

  Ballas, Z K ^a   Krieg, A M ^a   Warren, T ^a   Rasmussen, W ^a   Davis, H L ^a   Waldschmidt, M ^a   Weiner, G J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; OLIGODEOXYNUCLEOTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; CPG ISLAND; CYTOKINE RELEASE; IMMUNE RESPONSE; IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MELANOMA; METHYLATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF;

EID: 0035501012     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.9.4878     Document Type: Article

References (74)

1. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases
2. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective
3. CpG motifs in bacterial DNA trigger direct B-cell activation
4. CpG islands as gene markers in the vertebrate nucleus
5. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Thl) immunity
6. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
7. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of ThI responses by immunostimulatory DNA
8. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
9. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
10. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants
11. Type I interferon-mediated stimulation of T cells by CpG DNA
12. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth
13. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
14. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides
15. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
16. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
17. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation and airway hyperresponsiveness in mice
18. Long-term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
19. Mechanism of action of CpG DNA
20. Natural killer cells and tumor therapy
21. One hundred years of cancer immunotherapy: A critical appraisal
22. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs
23. Cyclosporine A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides
24. Selection of successive tumour lines for metastasis
25. Biological behavior of malignant melanoma cells correlated to their survival in vivo
26. Lymphokine-activated killer (LAK) cells IV. Characterization of murine LAK effector subpopulations
27. Nonparametric estimation from incomplete observations
28. Evaluation of survival data and two new rank order statistics arising in its consideration
29. Bacterial CpG DNA activates immune cells to signal infectious danger
30. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization
31. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte- macrophage colony- stimulating factor
32. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry
33. Mechanism and function of a newly identified CpG DNA motif in human primary B cells
34. Delineation of a CpG phosphorothioate oligonucleotide for activating primate immune responses in vitro and in vivo
35. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma
36. Expression of B7 co-stimulatory molecules by B16 melanoma results in a natural killer cell-dependent local anti-tumour response, but induces T- cell-dependent systemic immunity only against B7-expressing tumours
37. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
38. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma
39. Characterization of B16 melanoma-specific cytotoxic T lymphocytes
40. Long-term survival and complete cures of B 16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA
41. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide
42. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation
43. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
44. Natural killer cells in antiviral defense: Function and regulation by innate cytokines
45. The beige mutation in the mouse selectively impairs natural killer cell function
46. Generation and characterization of purified adherent lymphokine-activated killer cells in mice
47. A null mutation in the perforin gene impairs cytolytic T lymphocyte- and natural killer cell-mediated cytotoxicity
48. Phylogenetic perspectives in innate immunity
49. An ancient system of host defense
50. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
51. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria
52. CpG oligodeoxynucleotides trigger protective and curative Th I responses in lethal murine leishmaniasis
53. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-ω-dependent mechanisms
54. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines
55. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
56. Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously
57. CpG DNA can induce strong Thl humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
58. CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans
59. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys
60. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming
61. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma
62. Activation of human B cells by phosphorothioate oligodeoxynucleotides
63. Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN
64. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells
65. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism
66. Initial and innate responses to viral infections: Pattern setting in immunity or disease
67. Selective MHC expression in tumours modulates adaptive and innate antitumour responses
68. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
69. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
70. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge
71. Bacterial DNA induces in vivo IFN-γ Production by NK cells and increases sensitivity to endotoxin
72. Bacterial DNA causes septic shock
73. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo
74. Oligode-oxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice